Market open
Protara Therapeutics/$TARA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protara Therapeutics
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Ticker
$TARA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
31
Website
TARA Metrics
BasicAdvanced
$159M
-
-$2.17
1.68
-
Price and volume
Market cap
$159M
Beta
1.68
52-week high
$4.81
52-week low
$3.19
Average daily volume
323K
Financial strength
Current ratio
15.706
Quick ratio
15.536
Long term debt to equity
2.01
Total debt to equity
2.682
Management effectiveness
Return on assets (TTM)
-23.59%
Return on equity (TTM)
-37.88%
Valuation
Price to book
0.91
Price to tangible book (TTM)
0.91
Price to free cash flow (TTM)
-2.48
Growth
Earnings per share change (TTM)
-39.29%
3-year earnings per share growth (CAGR)
-19.85%
TARA News
AllArticlesVideos
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
GlobeNewsWire·2 days ago
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
GlobeNewsWire·2 weeks ago
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Protara Therapeutics stock?
Protara Therapeutics (TARA) has a market cap of $159M as of April 28, 2025.
What is the P/E ratio for Protara Therapeutics stock?
The price to earnings (P/E) ratio for Protara Therapeutics (TARA) stock is 0 as of April 28, 2025.
Does Protara Therapeutics stock pay dividends?
No, Protara Therapeutics (TARA) stock does not pay dividends to its shareholders as of April 28, 2025.
When is the next Protara Therapeutics dividend payment date?
Protara Therapeutics (TARA) stock does not pay dividends to its shareholders.
What is the beta indicator for Protara Therapeutics?
Protara Therapeutics (TARA) has a beta rating of 1.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.